|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, May 09, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, identifies four stocks on the move during the opening days of the current trading week.
It has been a rough couple of days for the markets as huge uncertainty in Europe and a stalling US recovery send shockwaves through the investing world, but there are still a few companies out there making news that are worth keeping an eye on. The broad downturn could also open up some solid buying opportunities that have the potential to turn into quick rebound stories once the markets recover.
Prolor Biotech (PBTH): Prolor Biotech (PBTH) opened the week as a stock on the move and continued that pattern on Tuesday with an early seven percent price rise on heavier-than-usual volume sparked by a Monday news report announcing positive top-line results from a Phase II four-month treatment extension study of hGH-CTP growth hormone deficient adults.
The data compiled from this study, according to Monday's release, "reaffirms the company's prior Phase II findings showing that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed human growth hormone (hGH), and further validates the dosing regimen for the company's planned Phase III trial."
Prolor has also recently initiated a Phase II trial in Europe testing hGH-CTP in pediatric applications, an event that confirms the thus far stellar record of the treatment since European regulators have stringent standards governing the initiatioin of clinical trials in children. Had the regulators not been overwhelmingly convinced that the treatment worked, then the green light would most likely not have been given to start testing in children.
Monday's encouraging data announcement adds to the growing list of positive developments for Prolor during the early portions of 2012 and illustrates the potential of hGH-CTP to replace a once-daily regimen of hormone injections for hormone-deficient patients with a once-weekly injection instead.
Additionally, Prolor owns world wide rights to the Carboxyl Terminal Peptide technology that allows for a once-weekly injection to replace once-daily injections in numerous protein therapies - aside for four fertility-related licenses to the technology that Merck (MRK) has successfully implemented in the European market - and the company is being staged to bring similar products to market in the treatment of Type II diabetes and obesity.
The last of those treatments, for the indication of obesity, could be an especially intriguing story if setbacks continue with Orexigen (OREX) and Vivus (VVUS), both of whom are looking to alleviate cardiovascular concerns relating to their repsective obesity treatments.
Safety concerns surrounding Arena's (ARNA) Lorcaserin treatment also have placed doubts on that company's chances with the FDA later this year, opening the door for Prolor to make headway in advancing its own treatment, which is a once-weekly version of Novo Nordisk's (NVO) one-daily protein injection.
The full version of this article which also includes coverage of TROV, AGEN and DNDN can be accessed by visiting:
http://vfcsstockhouse.com/blog/article/-stocks-on-the-move-pbth-dndn-trov-agen-gsk-orex-vvus-arna-mrk-nvo
For full report visit: http://vfcsstockhouse.com/blog/article/-immunocellular-therapeutics-imuc-any-pullback-may-mean-opportunity
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com 
Source: EmailWire.com
|
|
|
|
